These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21713039)

  • 21. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
    Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
    Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.
    Cowin RM; Roscic A; Bui N; Graham D; Paganetti P; Jankowsky JL; Weiss A; Paylor R
    Behav Brain Res; 2012 Apr; 229(2):308-19. PubMed ID: 22306231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.
    Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ
    J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease.
    Popoli P; Blum D; Domenici MR; Burnouf S; Chern Y
    Curr Pharm Des; 2008; 14(15):1500-11. PubMed ID: 18537673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
    Gonçalves N; Simões AT; Cunha RA; de Almeida LP
    Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
    Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
    Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.
    Garriga-Canut M; Agustín-Pavón C; Herrmann F; Sánchez A; Dierssen M; Fillat C; Isalan M
    Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3136-45. PubMed ID: 23054839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).
    Khan E; Tawani A; Mishra SK; Verma AK; Upadhyay A; Kumar M; Sandhir R; Mishra A; Kumar A
    ACS Chem Biol; 2018 Jan; 13(1):180-188. PubMed ID: 29172480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
    Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
    J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum.
    Chen CM; Wu YR; Chang KH
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease.
    Mievis S; Blum D; Ledent C
    Neurobiol Dis; 2011 Feb; 41(2):570-6. PubMed ID: 21062644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenic cellular phenotypes are germline transmissible in a transgenic primate model of Huntington's disease.
    Putkhao K; Kocerha J; Cho IK; Yang J; Parnpai R; Chan AW
    Stem Cells Dev; 2013 Apr; 22(8):1198-205. PubMed ID: 23190281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
    Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
    Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.